Glibenclamide nanosuspension inhaler: development,<i>in vitro</i>and<i>in vivo</i>assessment

Hashem, Fahima; Abd-Allah, Fathy I.; Abdel-Rashid, Rania S.; Hassan, Abdelsabour A.

doi:10.1080/03639045.2020.1753062

Cited by 12 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, after 180 mins the reduction in BGL was 23.41% and 61.78% for oral and NS inhaler, respectively. This highlights the potential and superiority of the NS inhaler over orally delivered glibenclamide immediately and after prolonged periods of time [178].…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 89%

Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

McGuckin

Wang

Ghanma

et al. 2022

Journal of Controlled Release

View full text Add to dashboard Cite

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 89%

Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

McGuckin

Wang

Ghanma

et al. 2022

Journal of Controlled Release

View full text Add to dashboard Cite

“…Maximum reduction in the blood glucose levels was noticed after 6 hours (33% for the nano-crystals and 24% for the micro-crystals) and then declined gradually till the values of 28.6 % and 20.4 at 24 hours, showing that longer action was obtained in comparison to the oral pure GB. For the diabetic rats, all treated groups showed considerable hypoglycemia when compared to diabetic control group 64 .…”

Section: H-nano-particlesmentioning

confidence: 93%

Strategies Adopted to Improve Bioavailability of Glibenclamide: Insights on Novel Delivery Systems

Nadeem

Abo‐zeid

Sakran

2023

Journal of Advanced Pharmacy Research

View full text Add to dashboard Cite

Objectives: Diabetes mellitus (DM) is one of the most prevalent chronic diseases worldwide. According to the statistics declared in 2020 by the World Health Organization [WHO], in the year of 1980, 108 million people have been diagnosed with diabetes mellitus worldwide, then, in 2014, that number had increased to 422 million. In 2020, International Diabetes Federation [IDF] has highlighted that; there will be nearly 700 million adults all over the world to be diagnosed with diabetes by the year of 2045. DM is sub-categorized into Type 1 and Type 2 DM. The former is considered as an autoimmune disorder, in which pancreatic β-cells are destructed, impairing insulin production. While Type 2 DM occurs due to loss of cells sensitivity to insulin. Both are associated with a marked increase in the blood glucose level (BGL) and hence, patients need for pharmacological treatment. T2DM is the most common among diabetic patients and its treatment involves the use of different classes like sulphonylureas, miglitinides and thiazolidinediones. Glibenclamide (GB) belongs to sulphonylureas, its low water solubility accompanied with lower bioavailability demands the use of a higher dose to assure proper management of diabetes. However, this is accompanied in some cases by a severe hypoglycemia that might be lethal in some cases. Therefore, finding a proper delivery system that could improve GB solubility is highly recommended. Nano-medicine could be considered as a promising strategy to improve the solubility and hence, bioavailability of GB. This review is exploring and presenting the recent studies performed to either to encapsulate GB into NPs or reduction of its size to the nano-size level, in order to improve its bioavailability. The review also points to the various obstacles facing nano-medicine clinical application and lack of human studies and sufficient long term safety studies suggesting that future work is needed to make a clearer conclusion about the clinical applicability of the nanodelivery of GB. Methods: This review reports a collection of research articles that investigated the use of several nanodelivery approaches for the delivery of GB up to 2022, using internationally accepted scientific journals and databases. Results: This review shows that the delivery of GB using nano-medicine strategy improves the GB aqueous solubility and hence, improves its oral bioavailability. It also shows that nano-medicine approach could sustain/control the release of GB, therefore, maintaining stable plasma drug concentration and avoiding any undesired fluctuation. Conclusion: The results of the collected articles show that the use of the different nano-medicine categories could be promising to overcome the poor bioavailability of GB. The successful clinical application of the liposomal delivery of certain drugs renders liposomes promising carrier for GB, however, because of the several advantages of the niosomes over liposomes, they seem to be a

show abstract

“…The temperature is ranged from 30 to 600 o C. nanocomposite. The FTIR spectra were measured via Perkin Elmer IR spectrophotometer from 400 to 4000 cm -1 at 4 cm -1 steps for disks composed of 2 mg sample/200 mg KBr [29].…”

Section: Thermogravimetric Analysismentioning

confidence: 99%

Tailoring nano-copolymer/CNTs composite and its application in drug delivery

et al. 2021

View full text Add to dashboard Cite

This work aimed to overcome the main drawbacks of some essential anticancer drugs as 5-Fluorouracil (5-FU) by controlled loading with novel drug carriers. By a differential microemulsion technique, nanosized particles derived from a copolymer of poly(methyl methacrylate (MMA) and 2-hydroxyethyl methacrylate (HEMA)) with different monomer ratios have been synthesized and used as a drug carrier. Poly(MMA-co-HEMA)/MWCNT nanocomposite was also synthesized using an in-situ microemulsion polymerization technique and used as a 5-FU carrier. Different techniques have characterized these groundbreaking drug delivery systems such as FT-IR, XRD, TEM, TGA, zeta potential, and a particle size analyzer. The effects of monomer feed composition, 5-FU content, and MWCNTs content on morphological and structural properties, in-vitro 5-FU release, and entrapment efficiency (EE%) have been studied. It was noted that the inclusion of MWCNTs in the 5-FU-loaded polymer increases the thermal stability and raises the entrapment efficiency (EE%) to hit 99% at CNTs:5-FU ratio of 2:1. The anticancer drug release from the co-polymeric nanospheres depends on the HEMA ratio, 5-FU/copolymer ratio, CNT/5-FU ratio, and the pH of the medium. The optimized nanocomposite demonstrated higher anti-tumor activity against the cell lines CaCo-2, MCF-7, and HepG-2 and higher cytotoxicity against HepG-2 relative to CaCo-2 and MCF-7.

show abstract

Glibenclamide nanosuspension inhaler: development,in vitroandin vivoassessment

Cited by 12 publications

References 38 publications

Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

Strategies Adopted to Improve Bioavailability of Glibenclamide: Insights on Novel Delivery Systems

Tailoring nano-copolymer/CNTs composite and its application in drug delivery

Contact Info

Product

Resources

About